Tel Aviv University Neuroimmunology Laboratory
Research to Prevent Cancer Recurrence
and Metastatic Disease
Ovarian cancer
Innovative research treatment for ovarian cancer patients undergoing surgery, to prevent cancer recurrence and prevent the development of cancer metastases.
-
The treatment is provided free of charge.
-
The drug treatment in the study is not a substitute for existing treatments.
-
Treatment begins 5 days before surgery and continues for about 11 weeks afterward.
-
The treatment is based on existing drugs marketed in Israel and internationally.
Who the research is intended for
-
Patients diagnosed with ovarian at all stages
-
Patients who are candidates for surgical tumor resection
-
Women aged 20 to 85
Who the research is not intended for
-
Patients who regularly consume beta-blocker or NSAID medications or are sensitive to these medications.
-
Patients with malignancy treated in the last 5 years
-
Patients with active asthma
Medical centers where
The research is underway.
-
Shamir Medical Center (Asaf Harofeh), Tzirifin.
-
Principal Investigator: Prof. Zvi Vaknin.
-
Iichilov Medical Center, Tel-Aviv Jaffa.
-
Principal Investigator: Prof. Nadav Mishan.
-
Sheba Medical Center, Ramat-Gan.
-
Principal Investigator: Dr. Anna blecher.
-
Assuta Medical Center, Ashdod.
-
Principal Investigator: Prof. Guy Harari.
-
Wolfson Medical Center, Holon.
-
Principal Investigator: Dr. Osnat Elishiv.
*A full examination regarding eligibility for the study will be conducted at the medical center.
When you arrive at your next appointment with your doctor, ask him/her about joining the study!